MeSH tree: D08
Researchers have identified a promising new target in the treatment of pancreatic cancer. A new study in The American Journal of Pathology demonstrates that blocking complement factor B (CFB), a pivotal enzyme in the alternative ...
18 hours ago
0
3
A phase 2b clinical trial led by Mass General Brigham Heart and Vascular Institute researchers shows that a monoclonal antibody therapy called MAR001 can significantly reduce triglyceride levels within 12 weeks for patients ...
Nov 9, 2026
0
29
A particular signaling protein in the brain could be a therapeutic target for neurological disorders arising from the deletion of the autism-linked gene MEF2C, University of Illinois Urbana-Champaign researchers found in ...
Nov 5, 2026
0
9
A new study led by King's College London has found that chemotherapy helps attract a specific population of immune cells called stem-like T cells toward tumors. The research, published in Cell Stem Cell, found that macrophages ...
Nov 5, 2026
0
71
A small subset of vulnerable DNA sites can make cancer cells highly sensitive to targeted drugs called PARP inhibitors, a new study shows. Led by researchers at NYU Langone Health and its Perlmutter Cancer Center, the work ...
Nov 5, 2026
0
17
Replacing dairy products, even partially, with unfortified plant-based alternatives may lead to a deficiency in vital nutrients, a new study from the University of Surrey reports. Mandatory fortification of plant-based alternatives ...
Nov 4, 2026
0
20
In a recent Yale-led clinical trial, a new type of prostate cancer drug showed promising results in reducing tumor activity and pain for patients with metastatic prostate cancer.
Nov 4, 2026
0
407
People with inflammatory bowel conditions such as ulcerative colitis often suffer from severe, long-lasting gut pain that lingers even after signs of inflammation are gone. Such abdominal pain can significantly affect one's ...
Researchers at Roswell Park Comprehensive Cancer Center have identified a promising strategy for overcoming one of the biggest challenges facing KRAS-targeted cancer therapies: treatment resistance. Results of the preclinical ...
Nov 2, 2026
0
3
Researchers at the Garvan Institute of Medical Research have discovered that the activity of a protein called CDK1 in breast cancers is linked to how they respond to a common therapy—an insight that could inform more personalized ...
Oct 30, 2026
0
34
